Regulation of Serum Response Factor and Adiponectin by  PPARγ Agonist Docosahexaenoic Acid by Johnson, Clayton et al.
Hindawi Publishing Corporation
Journal of Lipids
Volume 2011, Article ID 670479, 8 pages
doi:10.1155/2011/670479
Research Article
Regulation of Serum Response Factor and Adiponectin by
PPARγ Agonist Docosahexaenoic Acid
Clayton Johnson,1,2 Roslyn Williams,3 JeanneY. Wei,1 andGouriRanganathan1,3
1Donald W. Reynolds Institute on Aging University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot no. 748,
Little Rock, AR 72205, USA
2Biology Department, University of Arkansas at Pine Bluﬀ,P i n eB l u ﬀ, AR 71601, USA
3Central Arkansas Veterans Healthcare System, 4300 West 7th Street, Little Rock, AR 72205, USA
Correspondence should be addressed to Jeanne Y. Wei, weijeanne@uams.edu and Gouri Ranganathan,
ranganathangouri@uams.edu
Received 25 March 2010; Revised 18 June 2010; Accepted 3 August 2010
Academic Editor: Michel Lagarde
Copyright © 2011 Clayton Johnson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Recentstudiesindicatethatsigniﬁcanthealthbeneﬁtsinvolvingtheregulationofsignalingproteinsresultfromtheconsumptionof
omega-3 polyunsaturated fatty acids (ω-3 PUFAs). Serum response factor (SRF) is involved in transcriptional regulation of muscle
growth and diﬀerentiation. SRF levels are increased in the aging heart muscle. It has not been examined whether SRF is made
by adipocytes and whether SRF secretion by adipocytes is modulated by PPARγ agonist DHA. Adiponectin is made exclusively
by adipocytes. We and others have previously reported that PUFAs such as DHA increase adiponectin levels and secretion in
adipocytes. Here we show that DHA downregulates SRF with a simultaneous upregulation of adiponectin and that both these
responses are reversible by PPARγ antagonist. Furthermore, there appears to be a direct relationship between DHA exposure and
increased levels of membrane-associated high-density adiponectin, as well as lower levels of membrane-associated SRF. Thus, we
ﬁnd that the levels of SRF and adiponectin are inversely related in response to treatment with PPARγ agonist DHA. Decreased
levels of SRF along with increase in membrane-associated adiponectin could in part mediate the health beneﬁts of DHA.
1.Introduction
Advancing age is associated with increased risk of car-
diovascular disease, including development of metabolic
syndrome, dyslipidemia, insulin resistance, hypertension,
and atherosclerosis. Concurrent with the onset of these
disorders there is an increase in subcutaneous and visceral
adipose tissue, as well as ectopic fat within nonadipose
tissues, such as liver and striated muscle (heart and skeletal
muscle) [1]. This alteration in lipid distribution results in
a low-grade inﬂammatory response caused by increases in
inﬂammatory cytokines, such as interleukin 6 (IL-6) and
tumor necrosis factor alpha (TNF-α), secreted by invading
macrophages within the adipose depots. The adipose tissue,
both subcutaneous and visceral, maintains healthy circulat-
ing free fatty acid (FFA) levels, by regulating the equilibrium
between serum triglyceride and FFA levels during the fed or
fasted state.
Serum response factor (SRF) is a member of the MADS-
box family of transcription factors which work in conjunc-
tion with 60 diﬀerent cofactors to regulate a variety of
genes in many tissues during development, maturation, and
cell diﬀerentiation. Two major signaling pathways converge
on SRF, the ﬁrst or the classical MAPK pathway involves
growth factor-stimulated phosphorylation of SRF and the
second pathway involves Rho-dependent changes in actin
dynamics which drives SRF transcription [2, 3]. The protein
SRF is implicated in the transcriptional control of a number
of cardiac muscle genes which include cardiac α-actin,
skeletal α-actin, α-myosin heavy chain, and β-myosin heavy
chain that may have a role in the maintenance of cardiac
structure and function [4]. The cardiac muscle-speciﬁc
partialSRF-knock-outmousedisplaysadramaticdecreasein2 Journal of Lipids
SRF-target genes which are important to cardiomyocyte
function indicating that the contractile phenotype and the
calcium-handling properties of smooth muscle cells are
controlled by SRF [5]. Concomitant with the age-related
redistributionofadipose tissue,it hasbeenreportedthatcar-
diac levels of serum response factor (SRF) tend to increase,
and the age-associated increase in SRF appears to correlate
withdeclinesincardiachealth[6,7].Assummarizedrecently
by Miano [8], SRF plays a crucial role in the development
and maintenance of a normal cytoskeleton. Every organ
system relies on SRF for normal development and function,
and clinical data indicate that levels of SRF must be strictly
controlled to maintain cardiac homeostasis.
The adipose tissue is primarily an endocrine organ that
secretesadipocytokinesinresponsetochangesinphysiologic
stimuli, thus regulating the metabolic state. One of the
most abundant adipocyte-speciﬁc adipokines is adiponectin,
which plays a signiﬁcant role in regulating whole body
insulin sensitivity, anti-inﬂammatory responses, and cardiac
health. The adipocyte acts through the secretion of factors
involved in regulating triglyceride deposition in other tissues
[9]. It has been found that a modest overexpression of
adiponectin in ob/ob mice resulted in increased expan-
sion of the fat pads, relieving other tissues of triglyceride
deposition and normalization of metabolic phenotype [10].
The adverse side eﬀects of certain PPARγ agonists such
as thiazolidinediones that are used to manage diabetes
create an impetus for identifying alternative treatments that
may improve insulin sensitivity. Polyunsaturated fatty acids,
which act as agonists for both PPARγ and PPARα,a r ea
promising avenue for lowering of insulin resistance [11].
The long-chain ω-3 fatty acids, eicosapentaenoic acid (EPA),
and docosahexaenoic acid (DHA), which are prevalent in
certain cold-water ﬁsh oils but not in many other dietary
sources, have been shown to increase the levels of plasma
a d i p o n e c t i ni nr o d e n t sb yaP P A R γ-mediated mechanism
[12]. We have recently identiﬁed that ω-3 fatty acids, DHA,
and EPA increase adiponectin synthesis and secretion in
primary cultures of rat adipocytes. Saturated fatty acid
palmitatedoesnotincreaseadiponectin[13].SRFexpression
changes during development and adult aging, and it is
suggestedthatpreventingtheage-associatedelevationinSRF
is associated with beneﬁcial intracellular and physiological
functional response to stress, which is advantageous for the
older adult heart [7].
In the present paper we report that DHA regulates the
level of adiponectin and SRF. We observed that the inverse
regulation between adiponectin and SRF is modulated
throughthePPARγ-mediatedeﬀectsofDHA.Basedonthese
ﬁndings, we have studied the possible correlations between
ω-3 fatty acid (DHA) exposure and alterations in adipocyte
secretion and membrane association of adiponectin as well
as SRF.
2. Methods and Procedures
C57 BL6 mouse adipose tissues were obtained from healthy
5-6-month-old mice purchased from Harlem Sprague Daw-
ley. Animals were maintained, and experiments were con-
ducted according to approved protocols in accordance with
IACUC guidelines. Animals were euthanized by mild CO2
sedation followed by cervical dislocation. Epididymal fat
tissuewasusedtoprepareadipocytes,asdescribedpreviously
in [14, 15]. In brief adipose tissue was minced and digested
for 1 hour with 2mg/ml collagenase in 50mM HEPES buﬀer
containing Krebs-ringer salts, 3% BSA, and 5mM glucose.
The digested adipocytes were separated by centrifugation at
400×g for 1min. Under these conditions adipocytes ﬂoat
and the other tissue components sediment. Adipocytes were
recovered using a soft plastic pasture pipette. For experimen-
tal purposes adipocytes were incubated in DMEM/HEPES
(pH 7.5) supplemented with 1% BSA, 50U/ml of penicillin,
and 5μg/ml of streptomycin and treated with BSA conjugate
alone, DHA (25μM), or DHA (25μM) in the presence of
PPAR-γ inhibitor GW9962 (1.5μM) as indicated.
2.1. Cell Culture and Maintenance. 3T3-F442A cells were
obtained from Dr. Howard Green (Harvard Medical School,
Boston, MA). Cells were grown to conﬂuence and stimulated
to diﬀerentiate in DMEM (5mM glucose) containing 10%
fetal calf serum and 100nM insulin for 14 days [16].
For experiments adipocytes were maintained in DMEM
supplemented with 1% FBS or 1% BSA as speciﬁed.
2.2. Preparation of Fatty Acids. DHA (22:6, n3) (MP
Biomedicals) was dissolved in DMSO and conjugated to
fatty acid free BSA in a 2.5:1 ratio at 45
◦Cf o r3 0m i n u t e s .
The adipocytes were treated with 25μM DHA in presence
or absence of 1.5μMo fP P A R γ inhibitor, GW9662 (Sigma).
In cells being treated with DHA the DMSO concentration of
the medium was always less than 0.002%.
2.3. Western Blots for SRF and Adiponectin. 3T3 F442A
adipocytes or mouse adipocytes were incubated in DMEM
supplementedwith1%FBS,containingconjugatedfattyacid
for 16h. Cells were lysed in RIPA lysis buﬀer containing
protease inhibitor and analyzed on 10% SDS-PAGE followed
by Western blotting with SRF C-terminus antibody (Santa
Cruz) or adiponectin antibody (R&D systems). The SRF-
C-terminus antibody detects both full-length and cleaved
32kDa products of SRF [17]. Western bots were quantiﬁed,
and data are expressed as percent of control in arbitrary
units.
2.4. Fractionation of Adipocyte Medium Following Treatment
with DHA or DHA in the Presence of PPARγ Inhibitor
(GW9662). 5–20% sucrose gradients were prepared in
10mM HEPES and 125mM NaCl (pH 8), poured stepwise
(5, 10, 15, and 20%) in 2ml thin walled tubes and allowed
to equilibrate at 4◦C. Adipocyte conditioned medium is
fractionated on sucrose gradients as described earlier [18].
500μLofadipocyte-conditionedmediumcollectedafter16h
of incubation was layered on the gradient and separated
by ultracentrifugation at 310000×g for 4h using an SW60
Beckman rotor. Equal fractions were collected from the top
of the gradient for analysis by Western blots. Equal volumesJournal of Lipids 3
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Figure 1: Eﬀects of DHA on SRF and adiponectin in 3T3-F442A adipocytes. 3T3-F442A adipocytes diﬀerentiated as described in Methods
were treated with 25μMD H A ,2 5μM DHA plus 1.5μM GW9662 or 1.5μM GW9662 in DMEM containing 1% FBS for 16h. Cells were
lysed and separated on 10% SDS-PAGE followed by Western blotting with speciﬁc antibody. (a) Blots were analyzed with SRF C-terminus
antibody. (d) Bar graph shows quantiﬁcation using densitometric analysis of ≈65kDa SRF protein. Data in the bar graph represents means
of three independent experiments (∗P<. 025, #P<. 05). (b) The same blot was analyzed with β-actin antibody to examine equal loading
of proteins. (c) The same samples were also examined for the expression of adiponectin. Blots were probed with adiponectin antibody; bar
graph shows quantitation of adiponectin protein using densitometric analysis and is expressed as percent of control. (e) Data in the bar
graph represents means of three independent experiments (∗P<. 05, #P<. 05).
from each fraction were boiled with SDS sample buﬀer
containing β-mercaptoethanol and separated on 10% SDS-
PAGE. The proteins were transferred to PVDF membrane
for 1h at 250mA and probed with antiadiponectin, Flotillin,
or SRF antibody followed by HRP-conjugated secondary
antibody. Antibody binding was detected by enhanced
chemiluminescence (ECL) according to the manufacturer’s
speciﬁcation (Amersham Scientiﬁc, MA).
2.5. Total RNA Isolation and Real Time RT-PCR. RNA isola-
tion from primary cultures of mouse adipocytes treated with
DHA and real time PCR was performed as described earlier
by us [19]. Total RNA from adipose tissue was extracted
using an RNeasy Lipid Tissue extraction kit from Qiagen
(Valencia, CA). The quantity and quality of the isolated
RNA was determined using Agilent 2100 Bio analyzer (Palo
Alto, CA). Total RNA (0.5μg) was reverse transcribed using
randomhexamerprimerswithTaqManreversetranscription
reagents (Applied Biosystems, Foster City, CA). Reverse-
transcribed RNA was ampliﬁed with SYBR Green PCR
Master Mix (Applied Biosystems) plus 0.3mM of gene-
speciﬁc upstream and downstream primers during 35 cycles
on a Rotor-Gene 3000 using Real-Time Thermal Cycler
(Corbett Research, Sydney, Australia). Each cycle consisted
of denaturation at 94
◦C for 20s, annealing at 58
◦Cf o r2 0s ,
and extension at 72
◦C for 20s. Ampliﬁed 18S expression
was used as a standard control to normalize the diﬀerences
in individual samples. Primer sequences for mouse SRF4 Journal of Lipids
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Figure 2: SRF expression in mouse adipocytes treated with DHA. Equal volumes (1-2ml) of freshly isolated adipocytes were incubated in
DMEM-HEPES supplemented with penicillin-streptomycin, containing 1% BSA. Adipocytes were treated as speciﬁed control, 25μMD H A ,
25μM DHA plus 1.5μM GW9662, or 1.5μM GW9662 alone for 16h. Cells and medium were separated and analyzed for SRF expression.
(a) Western blots of SRF expression in mouse adipocytes. (d) Data in the adjacent bar graph represents one of two experiments done in
duplicate(∗P<. 03, #P<. 05). (b) The blot from part A was probed with β-actin antibody. (c) Western blot of SRF expression in adipocyte
conditioned medium. Densitometric analysis of SRF expression in cells, and medium is expressed as a percent of control. (e) The bar graph
represents means of all replicate experiments (∗P<. 025, #P<. 025).
and mouse adiponectin RNA are described below. Data
are expressed in relation to 18S RNA. The data represent
arbitrary units that accurately compare the samples to each
other within that assay. The Ct values of the PCR reactions
were generally between 20 and 30 for all assays.
Mouse SRF (FR) 5 -TTGGGGCCCTCTCTCCAGCC.
(RV)5 -GGGGCCGGGCTCTTTTGACC.MouseAdiponec-
tin (FR) 5 -GTTGCAAGCTCTCCTGTTCC. (RV) 5 -ATC-
CAACCTGCACAAGTTCC. 18S (FR) 5 -TTCGAACGT-
CTGC-3 .( R V )5  -ATGGTAGGCACGGCGACTA-3 .
2.6. Statistics. Data are expressed as mean ± SE, Student
T-test is used for statistical analysis, level of statistical
signiﬁcance is set at P ≤ .05.
3. Results
3.1. Eﬀect of DHA on SRF and Adiponectin Levels in
3T3-F442A Adipocytes. O u rp r e v i o u ss t u d i e sh a v es h o w n
that polyunsaturated fatty acids, DHA, and EPA increased
adiponectin synthesis and secretion via PPARγ-mediated
mechanisms in adipocytes, and saturatedfatty acid palmitate
at the same concentration did not alter adiponectin [13]. To
determine whether DHA treatment of adipocytes regulated
SRF levels via PPARγ-mediated mechanisms, 3T3-F442A
adipocytes were treated with 25μM DHA, 25μM DHA +
1.5μM GW9662, or GW9662 alone for 16h.
Adipocyte lysates were prepared in RIPA buﬀer con-
taining protease inhibitors, and 15μgp r o t e i ne x t r a c t sw e r e
separated on SDS-PAGE followed by analysis using WesternJournal of Lipids 5
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Figure 3: Fractionation of adipocyte medium following treatment with DHA or DHA in the presence of PPARγ inhibitor GW 9662. Mouse
adipocytes were treated: control (C), 25μM DHA (D), or 25 μM DHA plus 1.5 μM GW9662 (DI). Equal volumes of medium secreted from
treatments were fractionated on sucrose gradients and separated into 11 equal fractions as described in Methods. (a) Equal volumes of each
fraction were separated on SDS-PAGE gels and analyzed by Western blotting using adiponectin, Flotillin, or SRF antibody as described in
Methods. (b) Bar graph represents densitometric analysis of change in adiponectin and SRF expression following DHA treatment in each
fraction: DHA/Control.
blotting to detect SRF protein. SRF-C-terminus antibody
detected ≈65kDa full-length and ≈32kDa cleaved SRF
products as shown in Figure 1(a). Densitometric analysis of
the relative expression of 65kDa SRF is shown in the bar
graph.AsshowninFigure 1(a),SRFexpressionwasinhibited
by 85 ± 5% (P<. 025) following treatment with DHA. This
inhibitory eﬀect of DHA treatment was abolished by 40 ±
5% (P<. 05) in the presence of PPARγ inhibitor GW9662,
and the addition of PPARγ inhibitor GW9662 to adipocytes
increasedSRFexpression by50% (P<. 05).TheWesternblot
in Figure 1(a) represents one of three similar experiments.
The blot was subsequently probed with β-actin antibody to
compare the samples for equal protein loading. There was no
change in β-actin expression (Figure 1(b)).
The protein extracts from 3T3-F442A adipocytes (5μg
protein lysate) treated with 25μM DHA, 25μM DHA with
1.5μM GW9662, or GW9662 alone were analyzed for
adiponectin expression. Adiponectin protein in adipocyte
lysates was increased by 2-3-fold with DHA treatment (P<
.05), and the addition of PPARγ inhibitor along with DHA
abolished the increase in adiponectin signiﬁcantly (P<. 05).
PPARγ inhibitor alone did not alter adiponectin signiﬁcantly
as compared to control (Figure 1(c)). Blots were probed with
β-actin antibody to verify equal protein loading; there was
no change in β-actin (data not shown). The Western blot
shownrepresentsoneofthreesimilarexperiments.Bargraph
represents means of all three experiments.
3.2. SRF Expression in Primary Cultures of Mouse Adipocytes
Treated with DHA. We examined the eﬀect of DHA on
the regulation of SRF protein in freshly isolated primary
cultures of mouse adipocytes. Adipocytes were prepared
from epididymal fat pads of C57BL6 mice as described in
Methods and incubated for 16h in the presence of DHA
(25μM) or DHA + GW9662 (1.5μM) or GW9662(1.5μ)
alone. Cells and medium were collected separately; cells were
extracted in RIPA lysis buﬀer containing protease inhibitors
and analyzed for SRF expression using Western blots. As
shown in Figure 2(a), SRF protein was inhibited by 70±
10% by DHA treatment (P<.025). The addition of GW9662
(1.5μM) along with DHA decreased the inhibition partially
to 55±10% of the control (P<. 05), and the addition of
GW9662 alone increased SRF by 10±5% above the control.
The same blot was probed with β-actin antibody to verify
equal protein loading; there was no signiﬁcant change in
β-actin (Figure 2(b)). SRF secretion into the medium is
inhibited by DHA treatment 80±5% compared to control
(P<. 025), the addition of GW9662 along with DHA
increased SRF levels to 40±5% (P<. 05), and addition of6 Journal of Lipids
Table 1: SRF and adiponectin expression in mouse adipocytes.
Treatment Control DHA DHA +
GW9662 GW9662
SRF mRNA 1.442 ± 0.2 1.39 ±
0.13 1.20 ± 0.10 1.39 ± 0.2
Adiponectin
mRNA 3.1 ± 0.3 2.8 ± 0.12 2.8 ± 0.3 2.9 ± 0.2
Data are mean ± SD of two experiments done in triplicate.
SRFandadiponectinare expressed relativeto18S mRNAin arbitraryunits.
GW9662 to adipocytes increased SRF levels in the medium
to125 ±10%ofcontrol(P<. 05)(Figure 2(c));Westernblot
shown represents one of two experiments done in triplicate.
Bar graphs represent means from densitometric analysis of
all replicates from two experiments.
We examined SRF and adiponectin mRNA in primary
cultures of mouse adipocytes treated with DHA, DHA+
GW9662, or GW9662 alone for 16h. Changes in SRF and
adiponectin mRNA were measured with reference to 18s
RNA as described in Methods. There was no signiﬁcant
change in SRF mRNA or adiponectin mRNA expression
(Table 1). Plasma adiponectin increased following treatment
with PPARγ agonist thiazolidinedione and also by treatment
with ω-3 fatty acids [12]. However, a corresponding increase
in adiponectin mRNA expression was not detected in all
instances [12, 20]. In a previous study, PPARγ agonist-
pioglitazone increased plasma adiponectin but no corre-
sponding increase in adiponectin mRNA was found in sub-
cutaneous adipose tissues following pioglitazone treatment
of human subjects [21]. Treatment of rat adipocytes with
DHA or EPA increased cellular adiponectin protein with no
corresponding increase in mRNA [13].
3.3. Fractionation of Medium Secreted by Adipocytes on
Sucrose Gradients. It is known that PPARγ agonist increases
the adiponectin secretion in adipocytes [13, 22]. To examine
the coordinate regulation of adiponectin and SRF secretion
by DHA, primary cultures of mouse adipocytes were treated
with DHA (25μM) or DHA in the presence of PPARγ
antagonist, GW9662 (1.5μM).
Adipocyte-conditioned medium from control-, DHA-
and DHA + GW9662- treated adipocytes was centrifuged
at 3000×g to separate debris and fractionated on 5–20%
sucrose gradients as described in Methods. Equal volumes
(15μl) of fractionated medium from control, DHA, or DHA
+ GW9662 treated adipocytes were separated on 10% SDS-
PAGE, and all three blots were examined simultaneously
for adiponectin followed by Flotillin and SRF sequentially.
Adiponectin is known to be posttranslationally modiﬁed
into trimers, hexamer, and high molecular weight forms. As
shown in Figure 3(a) adipocyte-conditioned medium con-
tains adiponectin fractionating between fractions 1–7 and
fraction 11 of control adipocytes, DHA treatment increased
all isomeric forms of adiponectin by 2–10-folds in various
fractions, as indicated by densitometric analysis of frac-
tionated adiponectin (DHA/control) shown in Figure 3(b).
The DHA-mediated increase in adiponectin release was
abolished by the addition of PPARγ antagonist, GW9662
(Figure 3(a)). The same blots were then simultaneously
probed for the presence of Flotillin, which is a membrane
marker, to assess the membrane association of adiponectin
secretedbyadipocytes.FlotillinwasdetectedonlyinFraction
11 of control, DHA treated, and DHA + GW9662 treated
adipocytes. Fraction 11 is the densest fraction of the gradient
(20% sucrose) and Flotillin expression in fraction 11 did not
change with DHA treatment.
The same blots were deprobed and probed with SRF
antibody. SRF was detected in fractions 3, 4, 5, 6, and 11, in
conditioned medium fractionated from control adipocytes.
DHA treatment decreased SRF in fractions 3, 4, 5, 6,
and 11 (Figure 3(b)) and treatment with DHA + GW9662
(PPARγ antagonist)partiallyrestoredSRFlevelstoquantities
that are detectable after fractionation on sucrose gradients
(Figure 3(a)). The results in Figure 3 indicated that fraction
11 contained membrane marker Flotillin as well as both
adiponectin and SRF in the conditioned medium from
control adipocytes. These ﬁndings suggest that there is a
probable membrane association of both adiponectin and
SRF proteins.
4. Discussion
The molecular links between diabetes and cardiovascular
disease have not been fully understood. Adiponectin is
secreted by adipose tissue and is the most abundant protein
in plasma, second only to albumin [23]. Plasma adiponectin
levels inversely correlate with the risk for myocardial infarc-
tion, indicating that reduced adiponectin levels likely play
an important role in the pathogenesis of cardiovascular
disease. This hypothesis is also supported by previous
studies which indicate that adiponectin knock-out mice
have an increased cardiac ischemia/reperfusion injury and
this injury was partially attenuated by administration of
globular adiponectin [24]. SRF is known to regulate muscle
growth and diﬀerentiation [25]; aging also alters the levels
of SRF and factors regulated by SRF that promote muscle
regeneration [26].
Based on the signiﬁcance of both adiponectin and SRF
to cardiac health in the adult and aging population, we
have initiated experiments to understand the correlation
between increasing the healthy ω-3 fatty acids or DHA
and the resulting modulation of adiponectin and SRF at
the cellular level. Increasing plasma adiponectin level or
increasing adiponectin sensitivity with the aid of PPARγ
agonists has been proposed as a promising therapeutic
strategy for patients with metabolic and/or cardiovascular
disease [27]. Our previous studies in rat adipocytes and
3T3 F442A cells indicate that DHA increased both the
biosynthesis and release of adiponectin from, adipocytes and
the increase in adiponectin by DHA was blocked by PPARγ
antagonist [13]. Fish oil feeding for 15 days raised plasma
adiponectin levels in mice, and this increase in plasma
adiponectin was blocked by PPARγ inhibitor [12].
In the present study, we observed that DHA treatment
of adipocytes decreased SRF levels in both the cytosolic andJournal of Lipids 7
secreted fractions along with increases in adiponectin. The
decrease in SRF protein as well as the increase in adiponectin
by DHA treatment was reversible by the addition of PPARγ
antagonist indicating that both these processes are likely
to be PPARγ mediated. This is the ﬁrst report to our
knowledge showing the presence of SRF in adipocytes or as a
component of the adipocyte-secreted proteins. We ﬁnd that
DHA treatment of adipocytes decreases SRF protein levels as
well as SRF secretion with no corresponding decrease in SRF
mRNA expression, indicating that the decrease is mediated
likely through changes in post transcriptional processing. To
the best of our knowledge, the present study is the ﬁrst to
report the presence and secretion of SRF by adipocytes.
Furthermore,sucrosegradientfractionationofadipocyte
medium shows signiﬁcant increases in the levels of all
isomeric forms of the adiponectin after DHA exposure
and comigration of the high density form of adiponectin
with the integral membrane protein Flotillin. Our exper-
iments also indicated that DHA treatment of adipocytes
decreased the secretion of SRF and the appearance of SRF in
the membrane-associated adipocyte secreted fraction. This
observation indicates that the secreted high density form
of adiponectin might be membraneassociated. Most of the
beneﬁcialpropertiesofadiponectinhavebeenascribedtothe
HMW isoform which is known to have insulin sensitizing
properties as well as cardioprotective functions [28, 29]. It
is known that the presence of polyunsaturated fatty acids,
particularly ω-3 fatty acids in the cell membrane, increases
membrane ﬂuidity, which results in altering the association
of membranes with membrane proteins (receptors and
enzymes) [30]. The adipose tissue acts as an endocrine
organ by secreting the adipocytokines adiponectin, leptin,
resistin, TNF-alpha, and IL6, all of which serve to divert
lipid accumulation from muscle and liver to adipose tissue
thus regulating insulin sensitivity and inﬂammation as well
as cardiac health. Adiponectin, leptin, and resistin are made
in signiﬁcant quantities exclusively by adipocytes [9]. It
is also known that plasma adiponectin concentration is
decreased with ischemic heart disease and obesity and that
adiponectin has strong cellular protective properties, acting
through the AMPkinase- and cyclooxygenase-2-activated
mechanisms [31] .F u r t h e r m o r eS R Fi sam e m b e ro faf a m i l y
of transcriptional activators implicated in the regulation
of cell proliferation and diﬀerentiation through the reg-
ulation of the immediate early genes (IEGs) and many
signaling pathways. SRF levels in the heart are increased
with senescence and also in congestive heart failure [7].
Therefore it might be beneﬁcial that ﬁsh oils decrease SRF
secretion by adipocytes along with increasing the secretion
of adiponectin.
5. Conclusions
Based on these results, we conclude that DHA, which is
present in cold-water ﬁsh oils, triggers the induction of
adiponectin along with reducing the levels of SRF and
thereby likely mediate the desired protective downstream
eﬀects which are under investigation.
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